Frog-Derived GLP-1 Peptide AWRK6 Reverses Fatty Liver Disease in Mice
The synthetic peptide AWRK6, derived from frog antimicrobial peptide and acting as a GLP-1 receptor agonist, reversed fatty liver disease in mice by improving lipid and glucose metabolism through the PI3K/AKT/AMPK pathway.
Quick Facts
What This Study Found
AWRK6 (novel GLP-1R agonist from frog AMP) alleviated obesity and hepatic steatosis in HED-induced MAFLD mice, improved lipid and glucose metabolism, and activated PI3K/AKT/AMPK/ACC signaling. Confirmed in human HepG2 fatty liver cell model.
Key Numbers
Frog-derived AWRK6; GLP-1R agonist; reduced obesity/steatosis; PI3K/AKT/AMPK/ACC activated; confirmed in HepG2
How They Did This
In vitro and in vivo study. High energy diet-induced MAFLD mice treated with AWRK6 (IP injection). Biochemistry, liver histology, and signaling pathway analysis. Oleic acid-induced HepG2 fatty liver model and insulin sensitivity assays in human cells.
Why This Research Matters
MAFLD affects 25%+ of adults globally and has no approved drug. A peptide derived from a natural frog antimicrobial compound that acts through the GLP-1 pathway could represent a novel therapeutic approach, especially given that semaglutide is now being investigated for fatty liver.
The Bigger Picture
The discovery that a frog antimicrobial peptide can be repurposed as a GLP-1 receptor agonist for metabolic disease connects venom/AMP research to the booming GLP-1 drug market. Novel GLP-1 agonist peptides from unexpected natural sources could provide alternatives with unique properties.
What This Study Doesn't Tell Us
Mouse model with IP injection — not a practical clinical route. AWRK6 pharmacokinetics and oral bioavailability not assessed. Comparison to existing GLP-1 drugs not performed. Long-term safety unknown.
Questions This Raises
- ?How does AWRK6 compare to semaglutide for fatty liver treatment?
- ?Can AWRK6 be formulated for subcutaneous or oral delivery?
- ?Does AWRK6 have additional antimicrobial benefits beyond its GLP-1 activity?
Trust & Context
- Key Stat:
- Frog peptide → GLP-1 agonist A synthetic peptide originally designed from a frog antimicrobial compound unexpectedly acts as a GLP-1 receptor agonist, reversing fatty liver in mice
- Evidence Grade:
- Low-to-moderate evidence: combined in vitro (human cells) and in vivo (mouse) data with pathway elucidation. No clinical data.
- Study Age:
- Published 2021. GLP-1 drugs for fatty liver disease are now in clinical trials, with semaglutide showing promise.
- Original Title:
- A synthetic peptide AWRK6 ameliorates metabolic associated fatty liver disease: involvement of lipid and glucose homeostasis.
- Published In:
- Peptides, 143, 170597 (2021)
- Authors:
- Jin, Lili(2), Sun, Yuxin, Li, Yuying, Zhang, Hanyu, Yu, Wenxue, Li, Yiling, Xin, Yi, Alsareii, Saeed Ali, Wang, Qiuyu, Zhang, Dianbao
- Database ID:
- RPEP-05471
Evidence Hierarchy
Frequently Asked Questions
Can GLP-1 drugs help with fatty liver?
Growing evidence says yes. This study shows a novel GLP-1 agonist (AWRK6) reversed fatty liver in mice. Semaglutide (Ozempic) is also being tested for MAFLD in clinical trials. GLP-1 drugs may address fatty liver through improved glucose and lipid metabolism.
How was a frog peptide turned into a liver drug?
AWRK6 was originally designed from a frog skin antimicrobial peptide (Dybowskin-2CDYa). Researchers discovered it unexpectedly activated GLP-1 receptors — the same target as blockbuster diabetes/obesity drugs. This natural starting point provided a novel GLP-1 agonist with potential liver benefits.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05471APA
Jin, Lili; Sun, Yuxin; Li, Yuying; Zhang, Hanyu; Yu, Wenxue; Li, Yiling; Xin, Yi; Alsareii, Saeed Ali; Wang, Qiuyu; Zhang, Dianbao. (2021). A synthetic peptide AWRK6 ameliorates metabolic associated fatty liver disease: involvement of lipid and glucose homeostasis.. Peptides, 143, 170597. https://doi.org/10.1016/j.peptides.2021.170597
MLA
Jin, Lili, et al. "A synthetic peptide AWRK6 ameliorates metabolic associated fatty liver disease: involvement of lipid and glucose homeostasis.." Peptides, 2021. https://doi.org/10.1016/j.peptides.2021.170597
RethinkPeptides
RethinkPeptides Research Database. "A synthetic peptide AWRK6 ameliorates metabolic associated f..." RPEP-05471. Retrieved from https://rethinkpeptides.com/research/jin-2021-a-synthetic-peptide-awrk6
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.